Healthcare stocks are breaking out on fundamental wins — accumulate Eli Lilly
Healthcare and biotech stocks are surging on massive fundamental wins, from Eli Lilly's Medicare expansion to Moderna's FDA approval. With Goldman Sachs noting that broad capital spending is powering the bull market, defensive sectors with strong catalysts are attracting heavy institutional investment.
Idea
The healthcare sector is showing explosive, catalyst-driven growth that is completely detached from the volatility in tech and semiconductors. Eli Lilly just hit new highs thanks to Medicare inclusion for its GLP-1 drugs, representing a massive structural shift in its addressable market. Meanwhile, Moderna surged over 70% in a month following a unanimous FDA vote, showing that biotech sentiment can shift on a dime. Goldman Sachs highlights that broad capital spending is driving this bull market, and few sectors see as much direct capital deployment as pharmaceutical R&D and healthcare infrastructure. This combination of policy tailwinds and heavy investment makes healthcare a high-conviction long opportunity.
Key details
Community
News sources
- Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives? — Yahoo Finance
- Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results — Yahoo Finance
- Goldman Sachs Says Capital Spending Is Powering the Bull Market — Bloomberg